{"id":190350,"date":"2026-08-07T11:42:06","date_gmt":"2026-08-07T06:12:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=190350"},"modified":"2026-08-07T11:42:09","modified_gmt":"2026-08-07T06:12:09","slug":"jenburkt-pharma-q1-results-fy27-pat-5-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/","title":{"rendered":"Jenburkt Pharma Q1 FY27 Results: Revenue Rs 35 Cr, PAT Rs 5.00 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Jenburkt Pharma Q1 FY27 results declared Aug 6, 2026. Revenue Rs 35 Cr (-0.04% YoY). PAT Rs 5.00 Cr (-24.46% YoY). CMP Rs 1135.65 (-2.03%).<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/jenburph\/jenburkt-pharmaceuticals-ltd-share-price-today\">Jenburkt Pharma<\/a> Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. Jenburkt Pharma Q1 FY27 results show revenue declined -0.04% year-on-year to Rs 35 Cr from Rs 35 Cr in Q1 FY26, reflecting near-term headwinds in the Pharmaceuticals space. The broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index also reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit contracted -34.59% YoY to Rs 5 Cr from Rs 8 Cr, reflecting margin pressure from input costs and competitive dynamics. PAT fell -24.46% YoY to Rs 5.00 Cr from Rs 7.00 Cr in Q1 FY26. The quarterly numbers offer a detailed picture of how the company is navigating the current pharmaceuticals environment.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=jenburkt-pharma-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Jenburkt_Pharma_Q1_FY27_Financial_Highlights\" title=\"Jenburkt Pharma Q1 FY27 Financial Highlights\">Jenburkt Pharma Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Jenburkt_Pharma_Q1_FY27_Performance_Analysis\" title=\"Jenburkt Pharma Q1 FY27 Performance Analysis\">Jenburkt Pharma Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Key_Business_Factors_in_Jenburkt_Pharma_Q1_FY27_Results\" title=\"Key Business Factors in Jenburkt Pharma Q1 FY27 Results\">Key Business Factors in Jenburkt Pharma Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Revenue_Normalisation_After_Prior_Year_Headwinds\" title=\"Revenue Normalisation After Prior Year Headwinds\">Revenue Normalisation After Prior Year Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Operating_Profit_Under_Pressure_from_Cost_Headwinds\" title=\"Operating Profit Under Pressure from Cost Headwinds\">Operating Profit Under Pressure from Cost Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#PAT_Performance_and_Profitability_Trend\" title=\"PAT Performance and Profitability Trend\">PAT Performance and Profitability Trend<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#FY27_Outlook_for_Jenburkt_Pharma\" title=\"FY27 Outlook for Jenburkt Pharma\">FY27 Outlook for Jenburkt Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Jenburkt_Pharma_Stock_Performance_After_Q1_FY27_Results\" title=\"Jenburkt Pharma Stock Performance After Q1 FY27 Results\">Jenburkt Pharma Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Key_Risks_for_Jenburkt_Pharma\" title=\"Key Risks for Jenburkt Pharma\">Key Risks for Jenburkt Pharma<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Sector-Specific_Headwinds\" title=\"Sector-Specific Headwinds\">Sector-Specific Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Frequently_Asked_Questions_on_Jenburkt_Pharma_Q1_FY27_Results\" title=\"Frequently Asked Questions on Jenburkt Pharma Q1 FY27 Results\">Frequently Asked Questions on Jenburkt Pharma Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#When_were_Jenburkt_Pharma_Q1_FY27_results_declared\" title=\"When were Jenburkt Pharma Q1 FY27 results declared?\">When were Jenburkt Pharma Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#What_was_Jenburkt_Pharma_revenue_in_Q1_FY27\" title=\"What was Jenburkt Pharma revenue in Q1 FY27?\">What was Jenburkt Pharma revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#What_was_Jenburkt_Pharma_PAT_in_Q1_FY27\" title=\"What was Jenburkt Pharma PAT in Q1 FY27?\">What was Jenburkt Pharma PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#Did_Jenburkt_Pharma_declare_a_dividend_in_Q1_FY27\" title=\"Did Jenburkt Pharma declare a dividend in Q1 FY27?\">Did Jenburkt Pharma declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#What_is_the_FY27_outlook_for_Jenburkt_Pharma\" title=\"What is the FY27 outlook for Jenburkt Pharma?\">What is the FY27 outlook for Jenburkt Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/jenburkt-pharma-q1-results-fy27-pat-5-crore\/#How_did_the_Jenburkt_Pharma_stock_react_to_Q1_FY27_results\" title=\"How did the Jenburkt Pharma stock react to Q1 FY27 results?\">How did the Jenburkt Pharma stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Jenburkt_Pharma_Q1_FY27_Financial_Highlights\"><\/span><strong>Jenburkt Pharma Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #ffffff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDDDDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDDDDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDDDDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDDDDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Jenburkt Pharma Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">35<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">35<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD; color: red;\">-0.04%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">5<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">8<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD; color: red;\">-34.59%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">5.00<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">7.00<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD; color: red;\">-24.46%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\" colspan=\"3\">Standalone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Jenburkt_Pharma_Q1_FY27_Performance_Analysis\"><\/span><strong>Jenburkt Pharma Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Jenburkt Pharma Q1 FY27 results reflect pressure fundamentals across key financial parameters. Revenue momentum faced near-term headwinds with the top line reaching Rs 35 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit stood at Rs 5 Cr, contracting -34.59% YoY. Management is implementing cost reduction measures to restore operating leverage.<\/p>\n<p>PAT of Rs 5.00 Cr marks a -24.46% year-on-year improvement. Investors monitoring Jenburkt Pharma Q1 FY27 results will note this as a key milestone for FY27 tracking.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Jenburkt_Pharma_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Jenburkt Pharma Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Normalisation_After_Prior_Year_Headwinds\"><\/span><strong>Revenue Normalisation After Prior Year Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Jenburkt Pharma Q1 FY27 results reflect near-term revenue moderation of -0.04% YoY, attributed to market-specific factors including demand normalisation and channel inventory adjustments.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Profit_Under_Pressure_from_Cost_Headwinds\"><\/span><strong>Operating Profit Under Pressure from Cost Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Jenburkt Pharma Q1 FY27 results came in at Rs 5 Cr (-34.59% YoY), weighed down by input cost inflation, employee expenses, and competitive pricing dynamics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Performance_and_Profitability_Trend\"><\/span><strong>PAT Performance and Profitability Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit in Jenburkt Pharma Q1 FY27 results stood at Rs 5.00 Cr (-24.46% YoY). Near-term profitability moderation is being managed through cost optimisation initiatives.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was announced along with Jenburkt Pharma Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Jenburkt_Pharma\"><\/span><strong>FY27 Outlook for Jenburkt Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following Jenburkt Pharma Q1 FY27 results, management has reiterated its recovery roadmap, targeting operational efficiencies and revenue diversification to return to profitability. The pace of recovery in the Pharmaceuticals segment and macro tailwinds will be key monitorables. Investors tracking Jenburkt Pharma Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jenburkt_Pharma_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Jenburkt Pharma Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Jenburkt Pharma live price and get daily stock recommendations.<\/em><\/p>\n<p>Jenburkt Pharma shares were trading lower at Rs 1135.65 (-2.03%) on August 6, 2026, following the declaration of Jenburkt Pharma Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 1135.65 on the results date, with a 52-week range reflecting the broader market sentiment toward the pharmaceuticals sector.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Jenburkt_Pharma\"><\/span><strong>Key Risks for Jenburkt Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Headwinds\"><\/span><strong>Sector-Specific Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>US FDA regulatory actions, pricing pressure in generics, and USFDA import alerts remain core risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained margin compression and earnings visibility remain key concerns for investors in the near term.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jenburkt Pharma Q1 FY27 results demonstrate pressure financial performance with revenue at Rs 35 Cr and PAT at Rs 5.00 Cr on a Standalone basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Jenburkt_Pharma_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Jenburkt Pharma Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Jenburkt_Pharma_Q1_FY27_results_declared\"><\/span><strong>When were Jenburkt Pharma Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jenburkt Pharma Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Jenburkt_Pharma_revenue_in_Q1_FY27\"><\/span><strong>What was Jenburkt Pharma revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jenburkt Pharma Q1 FY27 results show revenue of Rs 35 Cr, -0.04% compared to Rs 35 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Jenburkt_Pharma_PAT_in_Q1_FY27\"><\/span><strong>What was Jenburkt Pharma PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit (PAT) in Jenburkt Pharma Q1 FY27 results was Rs 5.00 Cr, -24.46% year-on-year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Jenburkt_Pharma_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Jenburkt Pharma declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was declared alongside Jenburkt Pharma Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Jenburkt_Pharma\"><\/span><strong>What is the FY27 outlook for Jenburkt Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jenburkt Pharma management has outlined a focus on operational restructuring and return to profitability for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_the_Jenburkt_Pharma_stock_react_to_Q1_FY27_results\"><\/span><strong>How did the Jenburkt Pharma stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jenburkt Pharma shares were trading lower at Rs 1135.65 (-2.03%) on August 6, 2026, following the Jenburkt Pharma Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jenburkt Pharma Q1 FY27 results: Revenue Rs 35 Cr (-0.04% YoY), PAT Rs 5.00 Cr (-24.46% YoY). Key highlights, financial analysis and FY27 outlook.<\/p>\n","protected":false},"author":34,"featured_media":190349,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-190350","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["190349"],"_edit_lock":["1786083132:37"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Jenburkt Pharma Q1 FY27 Results: Revenue, PAT &amp; Key Highlights"],"rank_math_description":["Jenburkt Pharma Q1 FY27 results: Revenue Rs 35 Cr (-0.04% YoY), PAT Rs 5.00 Cr (-24.46% YoY). Key highlights, financial analysis and FY27 outlook."],"rank_math_focus_keyword":["Jenburkt Pharma Q1 FY27"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["37"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34874"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/jenburkt-pharma-q1-results-fy27-pat-5-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=190350"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190350\/revisions"}],"predecessor-version":[{"id":190377,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190350\/revisions\/190377"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/190349"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=190350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=190350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=190350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}